Big pharma look to smartphones and AI to improve outcomes
28-Aug-17, Business Korea
Global pharmaceutical companies such as Novartis, Pfizer and GlaxoSmithKline are accelerating the development of new drugs based on smartphones, artificial intelligence (AI) and big data. Korea, regarded as an IT powerhouse, urgently needs to change its recognition of such trials.
%20Business%20Korea.jpg "Big pharma look to smartphones and AI to improve outcomes (c) Business Korea")
Image: Business Korea
Medically advanced countries such as the US and European nations started early on with clinical research using mobile phones. Novartis recently launched a mobile clinical study using smartphone motion sensors for patients with multiple sclerosis. Its mobile clinical study used Apple's Research Kit.
The Korea Pharmaceutical & Bio-Pharma Manufacturers Association announced it will establish the Artificial Intelligence Drug Development Support Center, but a concrete method is not still on the way.